ChemicalBook > CAS DataBase List > Voriconazole

Voriconazole

Product Name: Voriconazole
CAS No.: 137234-62-9
Chemical Name: Voriconazole
Synonyms: Isopropyl 4-hydroxybutane-1-sulfonate;Voriconzole;(2R,3S)-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL;2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol;(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol;(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-;(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol;UK-10949;UK-109496;Voricozole
CBNumber: CB1160110
Molecular Formula: C16H14F3N5O
Formula Weight: 349.31
MOL File: 137234-62-9.mol

Less

Voriconazole Property

Melting point:: 127-130°C
alpha: D25 -62° (c = 1 in methanol)
Boiling point:: 508.6±60.0 °C(Predicted)
Density: 1.42±0.1 g/cm3(Predicted)
Flash point:: 9℃
storage temp.: 2-8°C
solubility: DMSO: >20mg/mL
form: white powder
pka: 11.54±0.29(Predicted)
color: White to Almost white
Merck: 14,10033
InChI: InChI=1/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/s3
InChIKey: BCEHBSKCWLPMDN-MGPLVRAMSA-N
SMILES: [C@@](C1C=CC(F)=CC=1F)(O)(CN1N=CN=C1)[C@H](C1=NC=NC=C1F)C |&1:0,16,r|
CAS DataBase Reference: 137234-62-9(CAS DataBase Reference)

Less

Safety

Hazard Codes: Xn,T,F
Risk Statements: 22-36/38-52/53-48/22-40-25-61-39/23/24/25-23/24/25-11
Safety Statements: 26-36-45-36/37-22-53-16
RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany: 3
RTECS: UV9145000
HazardClass: 6.1
PackingGroup: III
HS Code: 29335990

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

H341Suspected of causing genetic defects

H351Suspected of causing cancer

H361Suspected of damaging fertility or the unborn child

H371May cause damage to organs

H372Causes damage to organs through prolonged or repeated exposure

H373May cause damage to organs through prolonged or repeated exposure

H412Harmful to aquatic life with long lasting effects

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P273Avoid release to the environment.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: Y0001395
Product name: Voriconazole
Purity: European Pharmacopoeia (EP) Reference Standard
Packaging: 120 mg
Price: $236
Updated: 2025/07/31

Sigma-Aldrich

Product number: V-032
Product name: Voriconazole solution
Purity: 2.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant?
Packaging: 1mL
Price: $134
Updated: 2025/07/31

Sigma-Aldrich

Product number: 32483
Product name: Voriconazole
Purity: VETRANAL
Packaging: 25mg
Price: $148
Updated: 2025/07/31

Sigma-Aldrich

Product number: 1718008
Product name: Voriconazole
Purity: United States Pharmacopeia (USP) Reference Standard
Packaging: 100mg
Price: $425
Updated: 2025/07/31

TCI Chemical

Product number: V0116
Product name: Voriconazole
Purity: >98.0%(HPLC)
Packaging: 100mg
Price: $26
Updated: 2025/07/31

Less

Voriconazole Chemical Properties,Usage,Production

Description

Voriconazole is a broad-spectrum triazole antifungal ,it is primarily used for the treatment of progressive, possibly life-threatening infections in immune deficiency patients. Indications include: immunosuppressed patients with severe fungal infections, acute invasive aspergillosis (the most common pathogen is Aspergillus fumigatus, followed by A. flavus, Aspergillus niger and Aspergillus soil), severe invasive infections caused by fluconazole-resistant Candida (including C. krusei) severe infection caused by Foot actinomycetes bacteria genus and Fusarium bacteria genus . Moderate to severe renal insufficiency is administered intravenously paying caution.

Chemical Properties

Cyrstalline Solid

Originator

Pfizer (UK)

Uses

Voriconazole is an antifungal (systemic) that belong to an ergosterol biosynthesis inhibitor. It is used to treat serious fungal or yeast infections, such as aspergillosis (fungal infection in the lungs), candidemia (fungal infection in the blood), esophageal candidiasis (candida esophagitis), or other fungal infections (infections in the skin, stomach, kidney, bladder, or wounds).

Indications

Voriconazole (Vfend), a derivative of fluconazole, is a second-generation triazole that has improved antifungal activity against Aspergillus and Fusarium spp., P. boydii, Penicillium marneffei, and fluconazole-resistant Candida spp. Like fluconazole, voriconazole has high oral bioavailability and good cerebrospinal fluid penetration, but unlike fluconazole, it undergoes extensive hepatic metabolism and is highly protein bound. No significant amount of bioactive drug is excreted into the urine. Dosage reduction is necessary with severe hepatic insufficiency but not with renal insufficiency.

Definition

ChEBI: Voriconazole is a triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4. It has a role as a P450 inhibitor. It is a member of pyrimidines, a difluorobenzene, a tertiary alcohol, a triazole antifungal drug and a conazole antifungal drug.

brand name

Vfend (Pfizer).

Antimicrobial activity

The spectrum includes most fungi that cause human disease: dimorphic fungi (Blast. dermatitidis, Coccidioides spp., Hist. capsulatum, Paracocc. brasiliensis, Pen. marneffei and Spor. schenckii), molds (Aspergillus spp., Fusarium spp. and Scedosporium spp.), dematiaceous fungi and yeasts (Candida spp., Cryptococcus spp. and Trichosporon spp.).

Acquired resistance

Some fluconazole- and itraconazole-resistant strains of Candida and Aspergillus spp. show reduced susceptibility to voriconazole.

General Description

Voriconazole is a synthetically prepared, broad-spectrum triazole derivative of fluconazole, which shows in vitro activity against many yeasts and a broad-spectrum of mold and dermatophyte isolates. Its mode of action involves the inhibition of cytochrome P450 (CYP)-dependent enzyme, 14-α-sterol demethylase, and hence it is involved in disrupting the cell membrane and terminate the fungal growth.

Pharmaceutical Applications

Voriconazole is a triazole, antifungal agent that inhibits a broad range of pathogenic yeasts, including Candida (MIC = 0.03-8 μg/ml), and filamentous fungi such as Aspergillus, Scedosporium, and Fusarium. Its inhibitory action results from its ability to inhibit the synthesis of ergosterol, the major sterol of the fungal cell membrane.

Biological Activity

Voriconazole is an triazole antifungal agent used to treat serious fungal infections. It inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-α sterol demethylase resulting in a depletion of ergosterol in fungal cell membranes. Displays potent activity against Candida , Cryptococcus and Aspergillus species.

Pharmacokinetics

Oral absorption: 96%
C_max 400 mg oral: c. 2 mg/L after 2 h
Plasma half-life: c. 6 h
Volume of distribution: 4.6 L/kg
Plasma protein binding: 58%
Absorption
Oral absorption is rapid and almost complete, and is unaffected by intragastric pH. In adults, there is a disproportionate increase in blood concentrations with increasing oral and parenteral dosage, due to partial saturation of first-pass metabolism. In children given low dosages of the drug, proportional changes in drug levels are seen.
Distribution
It is widely distributed into body tissues and fluids, including brain and CSF.
Metabolism and excretion
It is extensively metabolized by the liver. More than 80% of a dose appears in the urine, but less than 2% is excreted in unchanged form. It is metabolized by several different hepatic cytochrome P₄₅₀ enzymes. Some people with point mutations in the genes encoding these enzymes are poor metabolizers while others are extensive metabolizers. Drug levels are as much as four-fold lower in individuals who metabolize the drug more extensively.

Clinical Use

Acute and chronic invasive aspergillosis
Serious invasive Candida infections
Serious infections caused by Scedosporium and Fusarium spp.

Side effects

Unwanted effects include mild to moderate visual disturbance, rashes, and transient abnormalities of liver enzymes. Rare side effects include life-threatening hepatitis.

Synthesis

The synthesis of voriconazole is an excellent example of process research. As depicted in the scheme, 5-fluorouracil (229) was chlorinated in both the 2- and 4- positions using a mixture of phosphorus oxychloride and N,N-dimethylaniline at 95?? C to afford 230 in 95% yield. Dichloro pyrimidine 230 was reacted with ethyl magnesium bromide to give dihydropyrimidine adduct 231. Adduct 231 was oxidized prior to quenching using a mixture of iodine and TEA in THF to give 2,4-dichloro-6-ethyl-5-fluoro pyrimidine (232) in 75% yield. Reaction of 232 with two equiv of aqueous NaOH at reflux gave selective displacement of the chloro functionality at 4-position. Acidification of the reaction and extraction with DCM gave 2-chloro-6-ethyl-5-fluoro-4(3H)- pyrimidine which was conveniently isolated as its ammonia salt 233. Dechlorination of 233 was achieved using catalytic hydrogenation at 50?? to provide 234 in 80% yield. Alternatively, 4-fluoro-6-ethyl-5-fluoropyrimidine (234) was prepared in a two-pot process in which methyl 3- oxopentanoate (235) was fluorinated with fluorine gas to give methyl 2-fluoro-3-oxopentanoate (236) in 80-90% yield. This ester was then cyclized with formamidine acetate in the presence of NaOMe to give 234 in a moderate yield (50-70%). Reaction of 234 with phosphorus oxychloride and TEA afforded 4-chloro-6-methyl-5- fluoropyrimidine (237) in 90% yield. Reaction of 237 with NBS in the presence of AIBN initiator provided bromide 238 in 95% yield. A Reformatsky protocol was employed in the condensation of 238 with ketone 239 which was an intermediate in the commercial synthesis of Diflucan. A solution of iodine in THF was added to a slurry of zinc and lead at rt and then a mixture of bromide 238 and ketone 239 were added to the above mixture at 5??C for 30 min. This provided the best diastereomeric selectivity and the ratio of 241 and 240 enantiomeric pair reached approximately 10 to 1. Adduct 241 was de-chlorinated using standard hydrogenation condition (5% w/w Pd on carbon /15 psi hydrogen) to give the racemate of voriconazole. The racemic voriconazole was resolved using (1R)-10-camphorsulfonic acid (242) and crystallization of the required diastereomeric salt provided optically pure voriconazole (28) in 80% yield.

Veterinary Drugs and Treatments

Voriconazole may be a useful treatment for a variety of fungal infections in veterinary patients, particularly against Blastomyces, Cryptococcus, and Aspergillus. It has high oral bioavailability in a variety of species and can cross into the CNS. Currently available human dosage forms are extremely expensive, however, and little clinical experience has occurred using voriconazole in veterinary patients. There is considerable interest in using voriconazole for treating aspergillosis in pet birds as their relative small size may allow the drug to be affordable; additional research must be performed before dosing regimens are available.

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: concentration of diclofenac, ibuprofen, alfentanil, methadone and oxycodone increased, consider reducing alfentanil and methadone dose; concentration of fentanyl possibly increased.
Anti-arrhythmics: avoid with dronedarone.
Antibacterials: concentration reduced by rifabutin; increase dose of voriconazole from 200 to 350 mg and from 100 to 200 mg (depends on patient’s weight), and increase IV dose to 5 mg/kg if used in combination - avoid concomitant use if possible; increased rifabutin levels - monitor for toxicity; concentration reduced by rifampicin - avoid.
Anticoagulants: avoid with apixiban and rivaroxaban; enhanced effect of coumarins.
Antidepressants: avoid concomitant use with reboxetine; concentration reduced by St John’s wort - avoid.
Antidiabetics: possibly increased concentration of sulphonylureas.
Antiepileptics: concentration possibly reduced by carbamazepine, phenobarbital and primidone - avoid; fosphenytoin and phenytoin reduces voriconazole concentration and voriconazole increases fosphenytoin and phenytoin concentration - double oral voriconazole dose and increase IV to 5 mg/kg dose if using with phenytoin; avoid if possible.
Antimalarials: avoid concomitant use with artemether/lumefantrine and piperaquine with artenimol.
Antipsychotics: concentration of lurasidone increased - avoid concomitant use; increased risk of ventricular arrhythmias with pimozide - avoid concomitant use; possibly increased quetiapine levels - avoid concomitant use.
Antivirals: concentration increased or decreased by atazanavir and concentration of atazanavir reduced; concentration of daclatasvir possibly increased - reduce daclatasvir dose; concentration possibly affected by darunavir; concentration reduced by efavirenz and ritonavir; also concentration of efavirenz increased - avoid with ritonavir; with efavirenz reduce dose by 50
% and increase dose of voriconazole to 400 mg twice daily; concentration possibly increased by simeprevir - avoid; concentration possibly affected by telaprevir - increased risk of ventricular arrhythmias; possibly increased saquinavir levels; concentration of simeprevir possibly increased - avoid.
Avanafil: possibly increased avanafil concentration - avoid.
Benzodiazepines: may inhibit metabolism of diazepam and midazolam.
Ciclosporin: AUC increased - reduce ciclosporin dose by 50
% and monitor closely.
Clopidogrel: possibly reduced antiplatelet effect.
Cytotoxics: possibly increases bosutinib concentration - avoid or reduce dose of bosutinib; possibly increases crizotinib and everolimus concentration - avoid; possibly increases ibrutinib, pazopanib and ponatinib concentration - reduce dose of ibrutinib, pazopanib and ponatinib; avoid with ceritinib, lapatinib, nilotinib, cabazitaxel and docetaxel (or reduce dose of cabazitaxel, ceritinib and docetaxel); reduce dose of panobinostat and ruxolitinib.
Domperidone: possible increased risk of arrhythmias - avoid.
Ergot alkaloids: risk of ergotism - avoid.
Ivacaftor and lumacaftor: possibly increase ivacaftor concentration - reduce dose of ivacaftor and ivacaftor with lumacaftor.
Lipid-lowering drugs: possibly increased risk of myopathy with atorvastatin or simvastatin; avoid with lomitapide.
Ranolazine: possibly increased ranolazine concentration - avoid.
Retinoids: possibly increased risk of tretinoin toxicity.
Sirolimus: increased sirolimus concentration - avoid.
Tacrolimus: AUC increased - reduce tacrolimus dose to a third and monitor closely.
Ulcer-healing drugs: esomeprazole and omeprazole concentration increased - reduce omeprazole dose by 50
%.

Metabolism

Voriconazole is metabolised by hepatic cytochrome P450 isoenzyme CYP2C19; the major metabolite is the inactive N-oxide. Metabolism via isoenzymes CYP2C9 and CYP3A4 has also been shown in vitro.
Voriconazole is eliminated via hepatic metabolism with less than 2
% of the dose excreted unchanged in the urine. After administration of a radiolabelled dose of voriconazole, approximately 80
% of the radioactivity is recovered in the urine as metabolites. The majority (>94
%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing

storage

Store at +4°C

Mode of action

Voriconazole is structurally related to fluconazole (Pfizer, diflucan) and acts by inhibiting the cytochrome P450- dependant enzyme 14a-sterol demethylase of ergosterol synthesis (thereby resulting in the formation of a cell membrane with abnormal characteristics and accumulation of toxic sterol intermediates). Voriconazole was more active than itraconazole and fluconazole against Cryptococcus neoformans and a variety of Candidas species such as C. albicans, C. glabrata C. krusei. It also exhibits similar or superior activity compared to amphotericin B and itraconazole against filamentous fungi such as Aspergillus, an important pathogen which is not susceptible to fluconazole.

Precautions

Significant drug interactions include cyclosporins(increased cyclosporine levels), phenytoin, rifampin,and rifabutin (decreased voriconazole levels). Becauseof its low toxicity profile, this drug may gain importancein the chronic treatment of infections with invasive dimorphicfungi and resistant Candida spp.

References

[1] sabo ja, abdel-rahman sm. voriconazole: a new triazole antifungal. ann pharmacother. 2000 sep;34(9):1032-43.
[2] johnson lb, kauffman ca. voriconazole: a new triazole antifungal agent. clin infect dis. 2003 mar 1;36(5):630-7.

Voriconazole Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Voriconazole Suppliers

Canada 2 China 601 Europe 3 Germany 4 India 77 Japan 1 Malta 1 South Korea 1 The Netherlands 1 United Kingdom 12 United States 50 Global 753

Beijing Lianben Pharm-Chemicals Tech. Co.,Ltd

Tel: 010-83386758 18810831598
Fax: 010-83386758
Email: sales@lianben.com
Country: China
ProdList: 94
Advantage: 58

Shandong Shengzhiyuan Biotechnology Co., LTD

Tel: 15064083436
Email: szyyy01@163.com
Country: China
ProdList: 75
Advantage: 58

Hubei Henghua Technology Co., Ltd.

Tel: 18064208139
Email: 2912268575@qq.com
Country: China
ProdList: 2987
Advantage: 58

Shandong Mingfeng Pharmaceutical and Technology Co. Ltd

Tel: -1345456643 15315114555
Fax: QQ:1345456643
Email: 1345456643@qq.com
Country: China
ProdList: 243
Advantage: 58

Chongqing Richem Biotechnology Co., Ltd.

Tel: 13983114937
Email: 382562851@qq.com
Country: China
ProdList: 78
Advantage: 58

Shanghai?Medlife?Pharm-Tech?Co.,?Ltd

Tel: 021-59167510 18117107507
Email: vip@med-life.cn
Country: China
ProdList: 5002
Advantage: 58

Shanghai Boyle Chemical Co., Ltd.

Tel: 021-50182298 021-50180596
Fax: +86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2208
Advantage: 55

J & K SCIENTIFIC LTD.

Tel: 18210857532; 18210857532
Fax: 86-10-82849933
Email: jkinfo@jkchemical.com
Country: China
ProdList: 96815
Advantage: 76

Meryer (Shanghai) Chemical Technology Co., Ltd.

Tel: 4006356688 18621169109
Fax: 86-21-61259102
Email: market03@meryer.com
Country: China
ProdList: 40228
Advantage: 62

3B Pharmachem (Wuhan) International Co.,Ltd.

Tel: 821-50328103-801 18930552037
Fax: 86-21-50328109
Email: 3bsc@sina.com
Country: China
ProdList: 15838
Advantage: 69

Chembest Research Laboratories Limited

Tel: +86-21-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6003
Advantage: 61

TAIYUAN RHF CO.,LTD.

Tel: +86 351 7031519
Fax: +86 351 7031519
Email: sales@RHFChem.com
Country: China
ProdList: 2338
Advantage: 56

TCI (Shanghai) Development Co., Ltd.

Tel: 021-67121386
Fax: 021-67121385
Email: Sales-CN@TCIchemicals.com
Country: China
ProdList: 24529
Advantage: 81

Beijing HwrkChemical Technology Co., Ltd

Tel: 18515581800 18501085097
Fax: 010-89508210
Email: sales.bj@hwrkchemical.com
Country: China
ProdList: 9400
Advantage: 55

Energy Chemical

Tel: 021-021-58432009 400-005-6266
Fax: 021-58436166
Email: sales8178@energy-chemical.com
Country: China
ProdList: 44801
Advantage: 61

Beijing Mediking Biopharm Co., Ltd

Tel: 010-81769521,89753524,81760121 15901403431
Fax: +86-10-81769652
Email: sales01@mediking.cn
Country: China
ProdList: 99
Advantage: 68

Capot Chemical Co., Ltd

Tel: +86 (0) 571 85 58 67 18
Fax: 0086-571-85864795
Country: China
ProdList: 18207
Advantage: 66

Jia Xing Isenchem Co.,Ltd

Tel: 0573-85285100 18627885956
Fax: 0573-85285100
Email: isenchem@163.com
Country: China
ProdList: 9310
Advantage: 66

Shanghai Longsheng chemical Co.,Ltd.

Tel: 021-58099652-8005 13585536065
Fax: 021-58099609
Email: bin.wu@shlschem.com
Country: China
ProdList: 9883
Advantage: 59

Beijing Lunarsun Pharmaceutical Co.,LTD.

Tel: 86-10-64911848-8020.8010
Fax: 86-10-64946614
Email: sales@lunarsun.com.cn
Country: China
ProdList: 95
Advantage: 60

Shanghai Hanhong Scientific Co.,Ltd.

Tel: 021-54306202 13764082696
Email: info@hanhongsci.com
Country: China
ProdList: 42934
Advantage: 64

Chemsky（shanghai）International Co.,Ltd.

Tel: 021-50135380
Email: shchemsky@sina.com
Country: China
ProdList: 32321
Advantage: 50

XiaoGan ShenYuan ChemPharm co,ltd

Tel: 15527621225
Email: 1791901229@qq.com
Country: China
ProdList: 6946
Advantage: 52

Hunan Hui Bai Shi Biotechnology Co., Ltd.

Tel: 0731-85526065 13308475853
Email: ivy@hnhbsj.com
Country: China
ProdList: 7247
Advantage: 62

S.Z. PhyStandard Bio-Tech. Co., Ltd.

Tel: 0755-83725681-603
Fax: +86 755 28094224
Country: China
ProdList: 4496
Advantage: 50

Beijing HuaMeiHuLiBiological Chemical

Tel: 010-56205725
Fax: 010-65763397
Email: waley188@sohu.com
Country: China
ProdList: 12335
Advantage: 58

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7552
Advantage: 61

9ding chemical ( Shanghai) Limited

Tel: 4009209199
Fax: 86-021-52271987
Email: sales@9dingchem.com
Country: China
ProdList: 22514
Advantage: 55

Shanghai Aladdin Bio-Chem Technology Co.,LTD

Tel: 400-6206333 13167063860
Fax: 021-50323701
Email: anhua.mao@aladdin-e.com
Country: China
ProdList: 25003
Advantage: 65

The future of Shanghai Industrial Co., Ltd.

Tel: 021-61552785
Fax: 021-55660885
Email: sales@shshiji.com
Country: China
ProdList: 9546
Advantage: 55

Hunan Furui Biopharma Technology Co., Ltd.

Tel: 1822-2954721 15901640172
Fax: 0731-57805668
Email: sales03@hn-furui.com
Country: China
ProdList: 421
Advantage: 55

Guangzhou Isun Pharmaceutical Co., Ltd

Tel: 020-39119399 18927568969
Fax: 020-39119999
Email: isunpharm@qq.com
Country: China
ProdList: 4720
Advantage: 55

Beijing Lianben Pharm-Chemicals Tech. Co., Ltd

Tel: +86-10-83386766
Fax: +86-10-83386758
Email: sales@lianben.com
Country: China
ProdList: 91
Advantage: 58

Nanjing Sunlida Biological Technology Co., Ltd.

Tel: 025-57798810
Fax: 025-57019371
Email: sales@sunlidabio.com
Country: China
ProdList: 3239
Advantage: 55

TargetMol Chemicals Inc.

Tel: 021-021-33632979 15002134094
Fax: 021-33632979
Email: marketing@targetmol.com
Country: China
ProdList: 7782
Advantage: 58

DONGSHENG CHIRAL PHARMA

Tel: 15800326364 18051538752
Email: 582512789@qq.com
Country: China
ProdList: 449
Advantage: 55

Sinfachem Limited

Tel: 025-84683399 13952017251
Fax: 025-84683112
Email: sales@sinfachem.com
Country: China
ProdList: 217
Advantage: 56

Wuhan DKY Technology Co.,Ltd.

Tel: 027-27-81302488 15972195220
Fax: 027-81302088
Email: info@dkybpc.com
Country: China
ProdList: 1758
Advantage: 58

Hubei XinyuanShun Chemical Co., Ltd.

Tel: 13971561712, 13995564702, 027-50664929
Fax: 027-50664927
Email: hbeixys2001@163.com
Country: China
ProdList: 3120
Advantage: 55

Megchem Co., Ltd.

Tel: +86 (21) 5471-7132
Fax: +86 (21) 5471-6993
Country: China
ProdList: 344
Advantage: 58

Bide Pharmatech Ltd.

Tel: 400-164-7117 13681763483
Fax: +86-21-61629029
Email: product02@bidepharm.com
Country: China
ProdList: 39966
Advantage: 60

ShangHai D&B Biological Science and Technology Co.Ltd

Tel: 400-008-9730,021-54359730 400-008-9730
Fax: 021-54353864
Email: info@chemxyz.com
Country: China
ProdList: 3057
Advantage: 60

ChemStrong Scientific Co.,Ltd

Tel: 0755-0755-66853366 13670046396
Fax: 0755-28363542
Email: sales@chem-strong.com
Country: China
ProdList: 18333
Advantage: 56

Sichuan Wei Keqi Biological Technology Co., Ltd.

Tel: 028-81700200 18116577057
Fax: 028-81705658
Email: 3003855609@qq.com
Country: China
ProdList: 7778
Advantage: 56

Finetech Industry Limited

Tel: 027-87465837 19945049750
Fax: 027-8777-2287
Email: sales@finetechnology-ind.com
Country: China
ProdList: 9637
Advantage: 58

Hunan HuaTeng Pharmaceutical Co., Ltd.,

Tel: 400-8592883
Fax: 0731-82251112
Email: sales@huatengsci.com
Country: China
ProdList: 5872
Advantage: 58

Suzhou yacoo science co.,Ltd

Tel: 0512-87182056 18013166090
Fax: 0512-87182056
Email: lingling.qi@yacoo.com.cn
Country: China
ProdList: 6295
Advantage: 60

NINGBO INNO PHARMCHEM CO.,LTD.

Tel: 86-574-27787657
Fax: 86-574-27912196
Email: info@dearchem.com
Country: China
ProdList: 4613
Advantage: 58

Wuhan Dahua Pharmaceutical Co., Ltd.

Tel: 027-59262863 13277907145 3091977954
Fax: 027-59420980
Country: China
ProdList: 4942
Advantage: 58

Shanghai YuLue Chemical Co., Ltd.

Tel: 021-60345187 13671753212
Fax: 021-34702061
Email: lzz841106@aliyun.com
Country: China
ProdList: 10263
Advantage: 55

Less

View Lastest Price from Voriconazole manufacturers

Shaanxi Dideu New Materials Co. Ltd

Product: Voriconazole 137234-62-9
Price: US $0.00-0.00/KG
Min. Order: 1KG
Purity: 98
Supply Ability: 10000KGS
Release date: 2025-12-01

Hefei Lbao Physical & Chemical Science Co.,Ltd

Product: Voriconazole 137234-62-9
Price: US $0.00/kg
Min. Order: 1kg
Purity: 98%
Supply Ability: Customise
Release date: 2025-11-20

ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD

Product: Voriconazole 137234-62-9
Price: US $2.00-5.00/kg
Min. Order: 1kg
Purity: 99%
Supply Ability: 100kg
Release date: 2025-06-18

137234-62-9, VoriconazoleRelated Search:

(2R,3S/2S,3R)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (2R,3S/2S,3R)-3-(4-Chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)butan-2-ol hydrochloride Candesartan Ravuconazole Ambroxol Itraconazole Human serum albumin Fluconazole Dexmedetomidine Linezolid Meropenem Tigecycline (+)-Griseofulvin Ceftriaxone sodium Nystatin Clindamycin (2RS, 3RS)-2-(2,4-Difluorophenyl)-3-(5-fluoropyriMidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol) 6-(1-Bromoethyl)-4-chloro-5-fluoropyrimidine

Voriconazole 2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol

Voriconazole solution

(2R,3S)-2-(2,4-Difluorophenyl)-3

2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1,2,4-triazol-1-yl)butan-2-ol

2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol

Voriconazole, >=98.5%

(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol

Voriconazole(UK 109496)

Voriconazole, 98%, a potent and broad-spectrum anti-fungal agent

Voriconazole USP

Voriconazole tab

Voriconazole - Vfend | UK 109496

(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-

Voriconazole≥ 99.9% (HPLC, Dried basis)

Voricozole

2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol

VORICONAZOLE

(2R,3S/2S,3R)-3-(5-FLUORO-4-PYRIMIDINYL)-2-(2,4-DIFLUOROPHENYL)-1-(1H-1,2,4-TRIA

(aR,bS)-a-(2,4-Difluorophenyl)-5-fluoro-b-methyl-a-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol

UK-10949

(2R,3S)-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL

(aR,S)-a-(2,4-Difluorophenyl)-5-fluoro--methyl-a-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol

UK-109496

Vorionazole

(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol

(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol

(R*,S*)-α-(2,4-Difluorophenyl)-5-fluoro-β-Methyl-α-(1H- 1,2,4-triazol-1-ylMethyl)-4-pyriMidineethanol

(αR,βS)-α-(2,4-Difluorophenyl)-5-fluoro-β-Methyl-α-(1H-1,2,4-triazol-1-ylMethyl)-4-pyriMidineethanol

Voriconazole RS

Voriconazole CRS

(αR,βS)-Voriconazole

Voriconzole

4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βS)-

Isopropyl 4-hydroxybutane-1-sulfonate

Voriconazole USP/EP/BP

Voriconazole DISCONTINUED

Voriconsrole

VoriconazoleQ: What is Voriconazole Q: What is the CAS Number of Voriconazole Q: What is the storage condition of Voriconazole Q: What are the applications of Voriconazole

Voriconazole (1718008)

voriconazole base

Voriconazole (UK-109, 496), anti-fungal agent

Voriconazole, 10 mM in DMSO

Voriconazole - Bio-X ?

Voriconazole 2.0 mg/ml in Methanol

4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1

4-triazol-1-yl)butan-2-ol

137234-62-9

137234-63-9

17234-62-9

1372116-67-6

C16H14N5OF3

C16H14F3N5O

Inhibitor

Fine Chemical

ZINACEF

antifungal

API